MAY 3 1 2007

PATENT Customer No. 22,852 Attorney Docket No. 9914.0004-00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Mary Jane Cardosa et al.	) Group Art Unit: 1648
Application No.: 10/786,380	) Examiner: STACY BROWN CHEN
Filed: February 24, 2004	Confirmation No.: 3579

For: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS

ANTIGENS AND THE USE THEREOF IN VACCINES

### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

 $\bowtie$ 

# **TRANSMITTAL LETTER**

In response to the Office Action dated March 1, 2007, Applicant submits the attached papers:

Applicant encloses an Amendment and Response (7 pages). The claims are calculated below:

	Claims Remaining		Highest Number	Present	Rate	Addi	tional
	After Amendment		Previously Paid	Extra		F	ee
Total	13	-	39	0	x \$ 50	\$	-0-
Indep.	1	-	3	0	x \$200		-0-
☐ First Presentation of Multiple Dep. Claim(s) +\$360							-0-
Subtotal						\$	-0-
Reduction by ½ if small entity						_	-0-
TOTAL						\$	-0-

No additional claims fee is required.

- Information Disclosure Statement (2 pages) with PTO Form SB-08 (1 page) and four (4) documents and required fee.
- \$180.00 Check for IDS Fee.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

Dated: May 31, 2007

Salvatore J/ Arrigo

Reg. No. 46,063

Telephone: 202-408-4160 Facsimile: 202-408-4160 E-mail: arrigos@finnegan.com



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mary Jane Cardosa et al. ) Group Art Unit: 1648

Application No.: 10/786,380 Examiner: STACY BROWN CHEN

Filed: February 24, 2004 ) Confirmation No.: 3579

For: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS

ANTIGENS, AND THE USE THEREOF IN VACCINES

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

# **AMENDMENT AND RESPONSE**

In response to the Office Action dated March 1, 2007, Applicant submits the following amendments and remarks.

Please amend the above-identified patent application as follows:

Amendments to the Specification are included in this paper.

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks begin on page 5 of this paper.